The stock of Altimmune, Inc. (NASDAQ:ALT) is now priced at $26.56 and the shares are 1.9 points up or 7.7% higher compared to its previous closing price of $24.66. The stock had 1.536 million contracts set over the past session. ALT shares’ daily volume is compared to its average trading volume at 5.096 million shares. However, it has a float of 11.91 million and although its performance was 1.78% over the week, it’s one to watch. It means the stock’s downside potential is -100% with the ALT share price recently placing at $24.59 to $26.75. However, some brokerage firms have priced the stock below the average, including one that has called $35.
The shorts are running away from the Altimmune, Inc. stock, with the latest data on short interest released on July 31, 2020, showing that short interest numbers in the ALT shares have declined. Short interest in the stock represents just 6.02% of its float, but the volume has dropped by -1461186. The volume of shorted shares dropped to 716730 from 2.178 million shares over the last two weeks. The average intraday trading volume has been 2.719 million shares, which means that days to cover moved to roughly 1.
In the last trading session, Altimmune, Inc. (NASDAQ:ALT) raised by $0.47 over the week and lost -$6.7 on its 20-day. The stock’s high in the recent session is lower when compared to its 52-week high of $35.1. The stock recorded its established 52-week high on 07/20/20.
Since 11/19/19, the stock has traded to a low of $1.51 at 1658.94%, an encouraging piece of data likely to interest most investors out to exploit the stock’s recent surge. The stock has a beta allocation of 2.15. Being above 1 means that the stock’s volatility is higher than the market and traders are keenly watching it.
Looking at current readings, Altimmune, Inc.’s two-week RSI is 58.12. This suggests that the stock is neutral at the moment and that ALT shares’ price movement remains stable. The stochastic readings are equally revealing at 50.14% meaning the ALT share price is currently in neutral territory.
The technical chart shows that the ALT stock will likely settle at between $27.34 and $28.13 per share. However, if the stock dips below $25.18, then its market would become much weaker. Any downside could see the stock price sliding to levels as low as $23.81.
Currently, the stock is trading in the red of MACD, with a reading of -0.33. Investors always pay attention to any move above or below the zero-line, mainly because the indicator points to the position of the stock’s short-term average relative to its long-term measure. A MACD -a reading above the zero line means that the short-term is above the long-term average. This scenario implies that there is an upward momentum. The opposite is true when the MACD falls below the zero-line.
Analysts at Maxim Group assigned ALT a rating of Outperform in their intiating review released on August 14. Piper Sandler analysts see the stock as a Overweight with a target price of $80 in a flash note released to investors on July 31 initiating covering the stock. JMP Securities analysts see the stock as Mkt Outperform when the analysts initiated the share price coverage on July 28, placing it at $50.
The average rating for the ALT equity is 2 and is currently gathering a bullish momentum. Of 3 analysts tracking Altimmune, Inc. polled by Reuters, 0 rated ALT as a hold. The remaining 3 analysts were split evenly. However, the split wasn’t equal as a majority (3) rated it as a buy or strong buy. 0 analyst advised investors against buying the stock or to sell if they own any of the stock.
Elsewhere, the ALT stock price is 10.73X ahead of its 12-month Consensus earnings per share estimates.
Zacks Consensus Estimate forecasts that the current-quarter revenues for Altimmune, Inc. (NASDAQ:ALT) will increase by about 35.81%, which will see them reach $980 million. The company’s full-year revenues are, however, expected to diminish by about -28.79%, down from $5.8 million to $4.13 million. ALT’s expected adjusted earnings should drop almost -2.74% to end up at -$0.71 per share, while for the fiscal year, analysts project the company’s earnings to grow by about 82.5% to record -$2.92/share.